Vizsgálati helyszín

GASTROMED Sp. z o.o.

Torun, 87 100, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve

35futó vizsgálat
13lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 49 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Colitis ulcerosa28 vizsgálat
Crohn-betegség24 vizsgálat
Coeliac disease2 vizsgálat
Arthritis psoriatica1 vizsgálat
Pikkelysömör1 vizsgálat
Fázis: 3. fázis24 vizsgálat
2. fázis20 vizsgálat
2/3. fázis3 vizsgálat
4. fázis2 vizsgálat
Állapot: Fut, nem toboroz19 vizsgálat
Toboroz16 vizsgálat
Lezárult13 vizsgálat
Felfüggesztve1 vizsgálat
Fő szponzor: Janssen Research & Development, LLC12 vizsgálat
AbbVie9 vizsgálat
Hoffmann-La Roche3 vizsgálat
Takeda3 vizsgálat
Alimentiv Inc.2 vizsgálat
és még 17

Futó vizsgálatok

Toboroz
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
2025-521590-13-00· 3. fázis· Janssen Cilag International· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Confirmatory Clinical Study in Active Ulcerative Colitis
NCT07296315· 2. fázis· MRM Health NV· Forrás
Toboroz
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615· 2. fázis· Takeda· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
NCT06636656· 2. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Fut, nem toboroz
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943· 2. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534· 3. fázis· AbbVie· Forrás
Toboroz
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706· 4. fázis· Alimentiv Inc.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
2023-506150-21-00· 2. fázis· Dr. Falk Pharma GmbH· Forrás
Fut, nem toboroz
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935· 3. fázis· Janssen-Cilag Ltd.· Forrás
Fut, nem toboroz
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950· 2. fázis· Takeda· Forrás
Toboroz
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461· 2. fázis· Takeda· Forrás
Toboroz
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05668013· 2. fázis· Teva Branded Pharmaceutical Products R&D LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095· 3. fázis· Janssen-Cilag Ltd.· Forrás
Fut, nem toboroz
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068· 3. fázis· AbbVie· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Lezárt vizsgálatok

Lezárult
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis
NCT07222189· 2. fázis· Sanofi-Aventis Recherche & Developpement· Forrás
Lezárult
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.
2023-507705-34-00· 3. fázis· Alvotech Swiss AG· Forrás
Lezárult
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.
NCT06637631· 2. fázis· Sanofi-Aventis Recherche & Developpement· Forrás
Lezárult
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis
2023-508679-34-00· 2. fázis· Anaptysbio Inc.· Forrás
Lezárult
A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease
NCT06001177· 2. fázis· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Forrás
Lezárult
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis
2022-503005-38-00· 2. fázis· Landos Biopharma Inc.· Forrás
Lezárult
A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and how safe it is compared to a licensed treatment called Entyvio®.
2022-502778-18-00· 3. fázis· Polpharma Biologics S.A.· Forrás
Lezárult
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
NCT05570006· 2. fázis· AbbVie· Forrás
Lezárult
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05499130· 2. fázis· Teva Branded Pharmaceutical Products R&D, Inc.· Forrás
Lezárult
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT04630028· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Determination of the Optimal Treatment Target in Ulcerative Colitis
NCT04259138· 4. fázis· Alimentiv Inc.· Forrás
Lezárult
An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
NCT02531126· 3. fázis· Celgene· Forrás

Helyszínadatok: ClinicalTrials.govFrissítve: 2026. nov. 14.

Hibát jelzek